Product image of Laventair Ellipta (Umeclidinium Bromide, Vilanterol) supplied by GNH India

Laventair Ellipta

Active Ingredient:
Umeclidinium Bromide, Vilanterol
Origin:
EU

Laventair Ellipta (Umeclidinium Bromide, Vilanterol)

Umeclidinium bromide / Vilanterol, the active ingredient in Laventair Ellipta, is a long‑acting muscarinic antagonist combined with a long‑acting β2‑agonist presented as an inhalation powder for inhalation use. It is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients, helping to improve lung function and reduce symptoms.

GNH India supplies Laventair Ellipta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Manufacturer / TM Owner

Glaxosmithkline Trading Services Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Laventair Ellipta is used in the management of chronic obstructive pulmonary disease (COPD), a progressive airway disease characterized by airflow limitation.

  • Chronic obstructive pulmonary disease (COPD): provides long‑term bronchodilation to improve airflow and reduce symptom burden.
  • Stable COPD: helps decrease the frequency of exacerbations.
  • COPD with persistent symptoms: enhances lung function and quality of life.

How It Works

  • Umeclidinium bromide binds to muscarinic M3 receptors on airway smooth muscle, blocking acetylcholine‑mediated contraction and preventing bronchoconstriction. Vilanterol selectively stimulates β2‑adrenergic receptors, activating adenylate cyclase and increasing cyclic AMP, which relaxes airway smooth muscle and promotes bronchodilation. The inhaled powder delivers both agents directly to the lungs, maximizing local effect while minimizing systemic exposure.

Side Effects

Laventair Ellipta may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Headache: mild to moderate headache reported.
  • Cough: transient cough after inhalation.
  • Upper respiratory tract infection: symptoms such as sore throat or nasal congestion.
  • Dry mouth: reduced salivation leading to oral dryness.

Serious or Rare Side Effects

  • Paradoxical bronchospasm: sudden worsening of breathing requiring medical attention.
  • Cardiovascular events: palpitations, tachycardia, or arrhythmias.
  • Allergic reactions: rash, angioedema, or anaphylaxis.

Precautions & Warnings

Before prescribing Laventair Ellipta, clinicians should consider several precautionary measures to ensure safe use.

  • Assess cardiovascular status: evaluate for uncontrolled arrhythmias or recent myocardial infarction.
  • Review respiratory history: avoid in patients with severe hypersensitivity to components.
  • Monitor for paradoxical bronchospasm: discontinue if symptoms worsen.
  • Caution in hepatic impairment: adjust monitoring as metabolism may be affected.
  • Use with other bronchodilators: consider additive effects on heart rate.
  • Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Laventair Ellipta can interact with other medicines, and awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

  • Beta‑blockers: may reduce bronchodilator effect and precipitate bronchospasm.
  • Monoamine oxidase inhibitors (MAOIs): increased risk of cardiovascular effects.
  • Anticholinergic drugs: additive anticholinergic burden may cause dry mouth or urinary retention.

Moderate Interactions (Monitor Closely)

  • Diuretics: may enhance hypokalemia risk when combined with β2‑agonist.
  • Theophylline: possible increase in plasma levels leading to toxicity.
  • Antihistamines: may increase anticholinergic side effects.

Frequently Asked Questions

Laventair Ellipta is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. It helps to improve airflow, reduce symptom severity, and lower the risk of exacerbations when used as part of a regular therapeutic regimen.

Umeclidinium bromide is a long‑acting muscarinic antagonist that binds to M3 receptors on airway smooth muscle. By blocking acetylcholine‑mediated signaling, it prevents bronchoconstriction, leading to sustained bronchodilation and improved lung function.

Vilanterol is a long‑acting β2‑adrenergic agonist. It stimulates β2 receptors on airway smooth muscle, activating adenylate cyclase and raising cyclic AMP levels, which relaxes the muscle and produces bronchodilation that lasts for at least 24 hours.

The prescribed dose is determined by the treating physician based on the patient’s clinical condition. Typically, one inhalation of the Ellipta device is taken once daily, but the exact regimen should follow the prescriber’s instructions and local labeling.

Safety data for use during pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant. Clinicians should discuss individual risk factors with the patient.

Enquiries can be submitted on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Laventair Ellipta combines a LAMA (umeclidinium) and a LABA (vilanterol) in a single once‑daily inhaler, offering convenience over separate agents. Compared with single‑component inhalers, the combination provides broader bronchodilation, potentially improving symptom control and adherence.

Store the inhaler at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the device is kept dry to maintain powder integrity.

The patient opens the Ellipta device, exhales fully away from the inhaler, places the mouthpiece between the lips, and inhales forcefully and deeply in a single breath. The inhaler then automatically returns to the closed position, indicating a successful dose.

Serious risks include paradoxical bronchospasm, which may worsen breathing and require immediate medical attention, and cardiovascular events such as tachycardia, arrhythmias, or palpitations. Patients should be monitored for these reactions, especially if they have underlying heart disease.

Laventair Ellipta is contraindicated in individuals with a known hypersensitivity to umeclidinium, vilanterol, or any excipients in the formulation. It should also be avoided in patients who have experienced severe paradoxical bronchospasm with similar inhaled bronchodilators.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Umeclidinium Bromide, Vilanterol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT